Psychedelics Show Promise in Chronic Pain Management, Substance Use Reduction, Study Finds
Last reviewed and updated: August 17, 2026.
Key Takeaways
| Two distinct areas | Psychedelics are studied both for substance use disorders and for chronic pain, but the evidence is stronger for substance use. |
| Substance use evidence | A 2022 randomized trial found psilocybin-assisted therapy reduced heavy drinking in alcohol use disorder, and small studies show promise for tobacco. |
| Chronic pain evidence | Pain research is earlier, with the strongest signal for cluster headache, plus preliminary work in fibromyalgia and other chronic pain. |
| Proposed mechanisms | Psychedelics may reduce addiction through psychological flexibility, and may ease pain through altered pain processing and reduced suffering. |
| Not approved | Nothing here is FDA-approved for pain or addiction, and classic psychedelics remain federally illegal, so this is research, not treatment. |
Recent research indicates that psychedelics may offer significant benefits for individuals suffering from chronic pain. A study published in the British Journal of Pain surveyed 466 adults who used psychedelics to manage chronic pain. The findings revealed notable reductions in the use of substances like alcohol and prescription opioids, alongside improvements in both physical and mental health.
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Key Findings from the Study
| Outcome | Percentage of Participants Reporting Reduction/Improvement |
|---|---|
| Reduced or stopped alcohol use | 71.1% |
| Reduced or stopped prescription opioid use | 64.1% |
| Reduced or stopped antidepressant use | 63.1% |
| Reduced or stopped illicit opioid use | 60.7% |
| Perceived improvement in physical health | 78.8% |
| Perceived improvement in mental health | 99.3% |
These findings suggest that psychedelics could serve as a valuable tool in chronic pain management, potentially reducing reliance on traditional substances and enhancing overall well-being.
RELATED: Watch Michael Pollan and Oprah Winfrey Discuss the Potential of Psychedelics
Psychedelics and Substance Use Reduction
The study highlighted that a significant majority of participants reduced or ceased using non-psychedelic substances after incorporating psychedelics into their pain management regimen. Specifically, 71.1% reduced or stopped alcohol consumption, and 64.1% did the same with prescription opioids. This trend indicates that psychedelics might help mitigate dependencies on substances commonly used for pain relief.
RELATED: MDMA’s Potential Role in Trauma Protection: A New Study on Nova Festival Survivors
Improvements in Health Outcomes
Beyond substance use reduction, participants reported substantial improvements in health. Approximately 78.8% experienced better physical health, while an impressive 99.3% noted enhancements in mental health. These self-reported outcomes underscore the potential of psychedelics to address both the physical and psychological aspects of chronic pain.
RELATED: Comic Bill Burr on Magic Mushrooms, Healing, and Overcoming Childhood Trauma
Mechanisms Behind the Benefits
The exact mechanisms through which psychedelics exert these effects remain under investigation. However, it’s hypothesized that psychedelics may promote neuroplasticity, leading to changes in perception and pain processing. Additionally, the profound experiences associated with psychedelics could foster a deeper connection to oneself and others, contributing to improved mental health and reduced substance reliance.
RELATED: Could Psychedelics Help Treat Hearing Loss? A Surprising Study in Mice Says Maybe
Considerations and Future Research
While the study’s findings are promising, it’s essential to approach them with caution. The reliance on self-reported data introduces potential biases, and the cross-sectional design limits the ability to establish causation. Moreover, the sample predominantly consisted of individuals from North America with an interest in psychedelics, which may not represent the broader population.
Future research should aim for larger, randomized controlled trials to validate these findings and explore the long-term safety and efficacy of psychedelics in chronic pain management. Understanding the appropriate dosing, administration methods, and potential risks is crucial before integrating psychedelics into mainstream medical practice.
In summary, the study offers compelling evidence that psychedelics may play a role in reducing substance use and improving health outcomes for individuals with chronic pain. As research progresses, psychedelics could emerge as a transformative approach in pain management and mental health treatment.
See also: Psychedelics Show Promise for Smoking Cessation, related HealingMaps coverage.
See also: A Single Dose of Psychedelics May Boost Memory, Study Finds, related HealingMaps coverage.
Psychedelics for Pain and Addiction: Where the Evidence Stands in 2026
Psychedelics have the stronger evidence base in substance use disorders. A 2022 randomized controlled trial found psilocybin-assisted therapy reduced heavy drinking days in people with alcohol use disorder. A small Johns Hopkins pilot showed promise for quitting smoking. Ibogaine has striking anti-addiction effects, but it carries serious cardiac risk. Substance use is the more developed area of this research.
The chronic pain evidence is earlier and more preliminary. The strongest pain signal is for cluster headache, supported by patient reports and some trial data. Researchers are also studying fibromyalgia, phantom limb pain, and chronic pain more broadly. Proposed mechanisms include altered pain processing and a reduced sense of suffering. Rigorous trials in this area are still limited.
Both areas are genuinely promising, but the substance use evidence is more developed than the chronic pain evidence. The two should not be treated as equally proven. Nothing here is FDA-approved for pain or addiction. Classic psychedelics remain federally illegal Schedule I substances. This is an active and hopeful research field, not a set of available treatments.
Frequently Asked Questions
- Can psychedelics help with addiction?
- The evidence is encouraging, especially for alcohol and tobacco. A 2022 randomized controlled trial found psilocybin-assisted therapy reduced heavy drinking in alcohol use disorder, and a small pilot showed promise for quitting smoking. Ibogaine has strong anti-addiction effects but serious cardiac risk. None of these are FDA-approved, so they remain investigational rather than available treatments.
- Do psychedelics help with chronic pain?
- The research is early and more preliminary than the addiction work. The strongest pain signal is for cluster headache, with some trial and patient-reported evidence, plus preliminary studies in fibromyalgia and other chronic pain. Psychedelics may ease pain by changing pain processing and reducing suffering, but rigorous trials are still limited, so this is promising rather than proven.
- Is the evidence stronger for pain or for addiction?
- For addiction. The substance use evidence, especially the 2022 psilocybin alcohol trial, is more developed than the chronic pain evidence, which remains earlier and more preliminary. Both areas are promising and under active study, but they should not be treated as equally proven. Chronic pain research is still in earlier stages.
- Are psychedelic treatments for pain or addiction legal?
- No. Classic psychedelics such as psilocybin and LSD remain federally illegal Schedule I substances, and none are FDA-approved for pain or addiction. The research is advancing and some results are striking, but these approaches are currently available mainly through clinical trials, not as approved treatments. Ibogaine in particular also carries serious cardiac risks.
